EGFR and non-small cell lung carcinoma: When further stratified by age, men age ≥ 65 with HR+ NSCLC had significantly greater prevalence of EGFR mutations (14/95, 14.74%) compared to HR- NSCLC (p= 0.0124, q=0.0289) while women age ≥ 65 with HR+ NSCLC had similar prevalence of EGFR mutations (39/171, 24.38%) compared to HR- NSCLC (121/644, 20.15%) (p=0.2357, q= 0.4125) (Table 3A).